Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 826 to 840 of 2042 results for guidelines

  1. Data collection agreement

    This agreement relates to treating cystic fibrosis patients with: Ivacaftor, tezacaftor and elexacaftor (Kaftrio®) in combination with ivacaftor for

  2. MTA process timeline

    These are the main stages in the multiple technology appraisal process used before April 2018. It applies to evaluations that started before 1...

  3. STA process timeline, pre-April 2018

    These are the main stages in the single technology appraisal (STA) process used before April 2018.

  4. Chemotherapy dose standardisation: NICE position statement

    NICE has been collaborating with NHS England on the Chemotherapy Dose Standardisation initiative which has been developed by the Medicines...

  5. Types of technology appraisal recommendation

    The technology appraisal committee can make 5 types of recommendation: Recommended, Optimised, Recommended for use in the Cancer Drugs Fund, Only in research, and Not recommended.

  6. Position statement on use of the EQ-5D-5L value set for England (updated October 2019)

    Our position on use of the EQ-5D-5L valuation set for England

  7. Modular updates for our technology appraisal guidance

    On this page, you'll find all our modular updates relating to our technology appraisal guidance. October 2023 NICE response to consultation on the...

  8. Biosimilar technologies: NICE position statement

    There are 2 different points of the lifecycle of a NICE Technology Appraisal at which consideration of reference to or inclusion of a biosimilar is...

  9. Biosimilar technologies: NICE position statement - information for the public

    Biosimilar medicines – NICE's approach A biological medicine is any medicinal product made by or derived from a biological (natural) source, for...

  10. How we develop medical technologies guidance

    It takes 38 weeks to develop a piece of medical technologies guidance. Timings are approximate and may change for some topics. The Medical...

  11. Register as a stakeholder

    Take part in the production of medical technologies guidance.

  12. Diagnostic technologies stakeholder registration

    Who can become a registered stakeholder? Registration is open to anyone with an interest in the topic who is one of the following: The company that

  13. Diagnostics Assessment Programme

    This guidance evaluates new, innovative diagnostic technologies. It includes all types of measurements and tests that are used to evaluate a patient's

  14. Diagnostics Assessment Programme process timeline

    These are the main stages in developing diagnostic technologies guidance. Timings are approximate. For a full description of the process see the:...

  15. Increasing use of health and social care data in guidance development

    We're aiming to increase and extend the use of data in the development and evaluation of our guidance. Data sources could include: electronic health